ImmunityBio Inc Ordinary Shares IBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
-
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
-
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
-
ImmunityBio Gets First Anktiva Authorization in Asia
-
ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva
Trading Information
- Previous Close Price
- $9.28
- Day Range
- $9.39–10.55
- 52-Week Range
- $1.95–12.43
- Bid/Ask
- $10.29 / $10.30
- Shares Outstanding
- 1.06B
- Market Cap
- $10.90B
- Volume/Avg
- 31M / 10M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 56.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 691
- Website
- https://www.immunitybio.com
Valuation
|
Metric
|
IBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 56.18 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IBRX
|
|---|---|
Quick Ratio | 5.35 |
Current Ratio | 5.72 |
Interest Coverage | −7.73 |
Quick Ratio
IBRX
Profitability
|
Metric
|
IBRX
|
|---|---|
Return on Assets (Normalized) | −122.56% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#rV@^@h | LOCK|LspXt | $128B | |||
| Moderna Inc
MRNA
| LOCK|$C$Vbd& | LOCK|!$ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|zKT#Kq | LOCK|J^#%y | $76B | |||
| argenx SE ADR
ARGX
| LOCK|mf%%VS | LOCK|@? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|N^&ZgrM | LOCK|t#% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cLGl$<< | LOCK|<?x#C | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|MY^tv%N% | LOCK|K!Dn | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|f$n#Mt# | LOCK|?V | $24B | |||
| Incyte Corp
INCY
| LOCK|X??<&L> | LOCK|bL | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&?qGp! | LOCK|!q$ | $15B |
United States